Hirudin is a potent thrombin inhibitor derived from the leech Hirudo medicinalis salivary gland which has considerable potential for therapeutic use in thrombotic disease. The major risk attendant its use is hemorrhage. This study investigates the hypothesis that the prohemostatic effects of DDAVP infusion can curtail the hemorrhagic effect induced by ongoing hirudin administration.
In a randomized and blinded manner, rabbits were exposed to a 15-min intravenous infusion of DDAVP or saline midway through a continuous two-h intravenous infusion of hirudin. Bleeding time was monitored by full thickness ear punctures performed before, during and after hirudin exposure.
Hirudin induced a significant hemorrhagic state, manifest as a 7-10-fold prolongation of the primary bleeding time. DDAVP reduced the mean duration of primary bleeding from 10.8 min to 5.9 min (p = 0.001) as well as the number of sites which bled for longer than 6 or 20 min (46% vs 27%, p = 0.002; and 18% vs 5%, p = 0.002, respectively). Although there was no difference in the incidence of spontaneous rebleeding from these sites (44 vs 36%, p = 0.21), rebleeding did not persist as long in animals that received DDAVP (8 vs 16 min, p = 0.005), and fewer sites rebled for longer than 20 min (8 vs 27%, p = 0.027). Results were essentially the same for two different commercial recombinant hirudin preparations.
DDAVP appears to attenuate the bleeding caused by continuous hirudin infusion in rabbits and establishes a foundation for clinical assessment in patients.
References
1
Haycraft JB.
On the action of a secretion obtained from the medical leech on the coagulation of blood. Proc Roy Soc London 1884; 36: 478
5
Abildgaard U.
Highly purified antithrombin III with heparin cofactor activity prepared by disc gel electrophoresis. Scand J Clin Lab Invest 1968; 21: 89-91
6
Harvey RP,
Degryse E,
Stefani L,
Schamber F,
Cazenave J-P,
Courteney M,
Tolstoshev P,
Lecocq J-P.
Cloning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986; 83: 1084-1088
7
Fortkamp E,
Reiger M,
Heisterberg-Moustes G,
Schweitzer S,
Sommer R.
Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 6: 511-517
8
Dodt J,
Schmitz T,
Schafer T,
Bergmann C.
Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence. FEBS Lett 1986; 202: 373-377
10
Maraganore JM,
Bourdon P,
Jablonski J,
Ramachandran KL,
Fenton III JW.
Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101
17
Francis CW,
Markham Jr RE,
Barlow GH,
Florack TM,
Dobrzynski DM,
Marder VJ.
Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-230
18
Weitz JI,
Hudoba M,
Massel D,
Maraganore JM,
Hirsh J.
Clot-blound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391
21
Jakubowski JA,
Maraganore JM.
Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the car-boxy-terminus of hirudin. Blood 1990; 75: 399-406
22
Heras MD,
Chesebro JH,
Penney WJ,
Bailey KR,
Badimon L,
Fuster V.
Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989 79. 657-665
24
Agnelli G,
Pascucci C,
Cosmi B,
Nenci GG.
The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63: 204-207
25
Klement P,
Brom A,
Hirsh J,
Maraganore J,
Wilson G,
Weitz J.
The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-68
26
Doutremepuich C,
Deharo E,
Guyot M,
Lalanne MC,
Walenga J,
Fareed J.
Antithrombotic activity of recombinant hirudin in the rat: A comparative study with heparin. Thromb Res 1989; 54: 435-445
27
Marder VJ,
Shortell CK,
Fitzpatrick PG,
Kim C,
Oxley D.
An animal model of fibrinolytic bleeding based on the rebleed phenomenon: Application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992; 67: 31-40
28
Walenga JM,
Pifarre R,
Hoppensteadt DA,
Fareed J.
Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: Some objective considerations. Sem Thromb Haemost 1989; 15: 316-333
29
Kaiser B,
Markwardt F.
Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613-620
32 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ila Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994 90. 1631-1637
33
Antman EM.
for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994 90. 1624-1630
34
Eriksson BI,
Kälebo P,
Ekman S,
Lindbratt S,
Kerry R,
Close P.
Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-231
35
Schiele F,
Vuillemenot A,
Kramarz P,
Kieffer Y,
Soria J,
Soria C,
Camez A,
Mirshahi MC,
Bassand JP.
A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-562
36
Ginsberg JS,
Nurmohamed MT,
Gent M,
MacKinnon B,
Sicurella J,
Brill-Edwards P,
Levine MN,
Panju AA,
Powers P,
Stevens P,
Turpie AGG,
Weitz J,
Büller HR,
ten Cate JW,
Neemeh J,
Adelman B,
Fox I,
Maraganore J,
Hirsh J.
Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-2389
37
MacGregor IR,
Roberts EM,
Prowse CV,
Broomhead AF,
Ozolins M,
Litka P.
Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. Thromb Haemost 1988; 59: 34-39
40
Ibbotson SH,
Grant PJ,
Kerry R,
Findlay VS,
Prentice CRM.
The influence of infusions of l-desamino-8-D-arginine vasopression (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP 39393) in vitro. Thromb Haemost 1991; 65: 64-66
41
Butler KD,
Dolan SL,
Talbot MD,
Wallis RB.
Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coag Fibrinoly 1993; 4: 459-464
43
Topol EJ,
Bonan R,
Jewitt D,
Sigwart U,
Kakker VV,
Rothman M,
de Bono D,
Ferguson J,
Willerson JT,
Strony J,
Ganz P,
Cohen MD,
Raymond R,
Fox I,
Maraganore J,
Adelman B.
Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-1629
45
Lidon R-M,
Théroux P,
Juneau M,
Adelman B,
Maraganore J.
Initial experience with a direct antithrombin, hirulog, in unstable angina. Anti-coagulant, antithrombotic and clinical effects. Circulation 1993; 88: 1495-1501
